Trial · NCT02235909
Adverse events264
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 264
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nasopharyngitis | Gastrointestinal disorders | Placebo Run-In | 289 | ||
| other | Nasopharyngitis | Gastrointestinal disorders | Losartan (Double-Blind Phase) | 3 | 53 | |
| other | Nasopharyngitis | Gastrointestinal disorders | AZM-L (Double-Blind Phase) | 0 | 52 | |
| other | Nasopharyngitis | Gastrointestinal disorders | AZM-M (Double-Blind Phase) | 3 | 56 | |
| other | Nasopharyngitis | Gastrointestinal disorders | AZM-H (Double-Blind Phase) | 2 | 54 | |
| other | Nasopharyngitis | Gastrointestinal disorders | Placebo (Withdrawal Phase) | 0 | 103 | |
| other | Nasopharyngitis | Gastrointestinal disorders | Losartan (Withdrawal Phase) | 23 | ||
| other | Nasopharyngitis | Gastrointestinal disorders | AZM-L (Withdrawal Phase) | 0 | 26 | |
| other | Nasopharyngitis | Gastrointestinal disorders | AZM-M (Withdrawal Phase) | 26 | ||
| other | Nasopharyngitis | Gastrointestinal disorders | AZM-H (Withdrawal Phase) | 25 | ||
| other | Nasopharyngitis | Gastrointestinal disorders | Azilsartan Medoxomil Alone | 0 | 156 | |
| other | Nasopharyngitis | Gastrointestinal disorders | Azilsartan Medoxomil PLUS | 5 | 41 | |
| other | Upper respiratory tract infection | Infections and infestations | Placebo Run-In | 289 | ||
| other | Upper respiratory tract infection | Infections and infestations | Losartan (Double-Blind Phase) | 0 | 53 | |
| other | Upper respiratory tract infection | Infections and infestations | AZM-L (Double-Blind Phase) | 5 | 52 | |
| other | Upper respiratory tract infection | Infections and infestations | AZM-M (Double-Blind Phase) | 0 | 56 | |
| other | Upper respiratory tract infection | Infections and infestations | AZM-H (Double-Blind Phase) | 0 | 54 | |
| other | Upper respiratory tract infection | Infections and infestations | Placebo (Withdrawal Phase) | 0 | 103 | |
| other | Upper respiratory tract infection | Infections and infestations | Losartan (Withdrawal Phase) | 23 | ||
| other | Upper respiratory tract infection | Infections and infestations | AZM-L (Withdrawal Phase) | 2 | 26 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02235909/events